Efficacy of prolonged adjuvant imatinib in gastrointestinal stromal tumors: a systematic review and exploratory network meta-analysis
Three years of adjuvant imatinib is the established standard for patients with high-risk gastrointestinal stromal tumors (GIST), but recurrence after treatment cessation raises questions about longer treatment durations. This study evaluated evidence on extended adjuvant therapy, emphasizing treatment beyond 3 ye...